A METHOD OF MODULATING THE EFFICIENCY OF TRANSLATION TERMINATION AND DEGRADATION OF ABERRANT MRNA INVOLVING A SURVEILLANCE COMPLEX COMPRISING HUMAN UPFLP, EUCARYOTIC RELEASE FACTOR 1 AND EUCARYOTIC RELEASE FACTOR 3

摘要

This invention provides a method of modulating translation terminationefficiency of mRNA and/or promoting degradation of aberrant transcripts. Also,this invention provides a method of screening for a drug active involved inenhancing translation termination and a method for identifying a disease stateinvolving defective the protein complex. This invention provides a purifiedcomplex comprising an amount of a human Upflp protein, a peptidyl eucaryoticrelease factor 1 (eRF1) and a peptidyl eucaryotic release factor 3 (eRF3)effective to modulate translation termination. Further, this inventionprovides an expression vector which comprises a nucleic acid encoding a humanUpflp protein, a peptidyl eucaryotic release factor 1 (eRF1) and a peptidyleucaryotic release factor 3 (eRF3) operably linked to a regulatory element.This invention provides an antibody which binds to the complex comprising anamount of a human Upflp protein, a peptidyl eucaryotic release factor 1 (eRF1)and a peptidyl eucaryotic release factor 3 (eRF3)effective to modulatetranslation termination. This invention provides an agent which inhibits ormodulates the binding of human Upflp to eRF1 or eRF3. The agent may inhibit orfacilitate the binding of human Upflp to eRF1 or eRF3.